A Phase II Study of Axitinib to Treat Patients with Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma

Full Title

Phase II Study of Axitinib in Patients with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Purpose

Axitinib is an anticancer drug that inhibits the growth of the blood vessels that cancers need to grow and spread. It is approved for treating a type of kidney cancer called renal cell carcinoma. In this study, researchers are assessing the safety and effectiveness of axitinib in patients who have neurofibromatosis type 2 with progressive vestibular Schwannomas. Axitinib is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have neurofibromatosis type 2 with at least one vestibular Schwannoma that is continuing to grow.
  • At least 4 weeks must pass between the completion of previous treatments and entry into the study.
  • This study is for patients age 5 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthias Karajannis at 212-639-3171.

Protocol

17-273

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators